<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542579</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1010691</org_study_id>
    <nct_id>NCT02542579</nct_id>
  </id_info>
  <brief_title>Gastric and Duodenal Microbiota in Dyspeptic Subjects</brief_title>
  <official_title>Composition of Gastric and Duodenal Microbiota in Dyspeptic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of gastric microbiota is determined by the status of Helicobacter pylori
      infection. In subjects who have never been infected by H. pylori, gastric microbiota includes
      various bacteria, creating ideal microbial diversity. This ideal microbial diversity is
      destroyed by H. pylori infection at low intragastric pH. Since it is difficult for most
      bacteria to proliferate within an acidic stomach, relative H. pylori abundance gives rise to
      microbial dysbiosis. Conversely, unideal microbial diversity is often observed in infected
      individuals with impaired gastric secretory ability at hypochlorhydric condition. Bacteria
      producing carcinogenic N-nitrosamine compounds are often detected in individuals with past or
      chronic H. pylori infection at high intragastric pH. Nonetheless, microbial imbalance that
      occurs in the earlier phase before gastric carcinognenesis is uncertain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dominant colonization of a specific microbiota leading to dysbiosis may lead to inflammation
      of the mucosa. We hypothesized that the degree of inflammation depend on the composition of
      microbiota. This study was aimed to define gastric and duodenal microbiota leading to
      abnormal histopathology. We further tried to elucidate whether the composition of duodenal
      microbiota is altered by gastric microbiota.

      Among the dyspeptic subjects who visited for upper gastrointestinal (UGI) endoscopy, subjects
      with drug intake (antibiotics, PPIs, laxatives, antidepressants, statins, metformin) within 3
      months will be excluded. Three biopsies will performed at the greater curvature side of the
      mid-antrum, greater curvature side of the mid-body, and at the duodenum, respectively. Next
      generation sequencing analysis will be performed for 16S rRNA variable regions using the
      biopsied samples.

      Primary study endpoint is 16S rRNA sequencing findings of gastric and duodenal microbiota.

      Secondary endpoints are microbiota linked with higher degrees of inflammation, activity,
      atrophy and intestinal metaplasia based on the updated Sydney classification. Furthermore,
      correlation between the microbiota and endoscopy finding will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Next generation sequencing analysis for microbiota</measure>
    <time_frame>up to 6 months</time_frame>
    <description>16S rRNA pyrosequencing analysis findings of the gastric and duodenal biopsies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Updated Sydney classification</measure>
    <time_frame>up to 6 months</time_frame>
    <description>0=none, 1=mild, 2= moderate, 3=marked infiltration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal endoscopy finding</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Upper gastrointestinal endoscopy findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptom and food intake score</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Scoring system published in Neurogastroenterol Motil 2016;28:1401-1408</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Microbial Colonization</condition>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Subjects for pyrosequencing analysis</arm_group_label>
    <description>Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>16S rRNA pyrosequencing analysis</intervention_name>
    <description>Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).</description>
    <arm_group_label>Subjects for pyrosequencing analysis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gastric and duodenal mucosa
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Dyspeptic subjects for analysis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dyspeptic subjects who visited for evaluation including upper gastrointestinal
             endoscopy and biopsies

          -  Age &gt;20 years old

        Exclusion Criteria:

          -  Underlying disease(s) that requires managements

          -  Recent intake of drug(s)

          -  History of gastrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun-Young Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee SY, Moon HW, Hur M, Yun YM. Validation of western Helicobacter pylori IgG antibody assays in Korean adults. J Med Microbiol. 2015 May;64(Pt 5):513-518. doi: 10.1099/jmm.0.000050. Epub 2015 Mar 9.</citation>
    <PMID>25752852</PMID>
  </reference>
  <reference>
    <citation>Lee SP, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Moon HW. Correlation between Helicobacter pylori infection, IgE hypersensitivity, and allergic disease in Korean adults. Helicobacter. 2015 Feb;20(1):49-55. doi: 10.1111/hel.12173. Epub 2014 Sep 25.</citation>
    <PMID>25257099</PMID>
  </reference>
  <reference>
    <citation>Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol. 2012 Feb;27(2):200-11. doi: 10.1111/j.1440-1746.2011.06961.x. Review.</citation>
    <PMID>22098099</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>August 5, 2018</last_update_submitted>
  <last_update_submitted_qc>August 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Sun-Young Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

